# Trial to Evaluate the Efficacy, Safety and Pharmacokinetics of RBD1016 in Participants With Chronic Hepatitis D

> **NCT06649266** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Ribocure Pharmaceuticals AB** · enrollment: 14 (actual)

## Conditions studied

- Chronic Hepatitis D

## Interventions

- **DRUG:** RBD1016
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06649266
- **Lead sponsor:** Ribocure Pharmaceuticals AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-08-21
- **Primary completion:** 2026-09
- **Final completion:** 2027-08
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2026-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06649266

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06649266, "Trial to Evaluate the Efficacy, Safety and Pharmacokinetics of RBD1016 in Participants With Chronic Hepatitis D". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT06649266. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*